Linda Montanari, Buenos Aires, 22-24 October 2003 CICAD/OAS, Demand Reduction Experts Group Meeting The Information System on Treatment Demand in EU EMCDDA.

Slides:



Advertisements
Similar presentations
Estimating incidence of heroin use from treatment data presentation for TDI expert meeting Lucas Wiessing (EMCDDA), Lucilla Ravà and Carla Rossi (Univ.
Advertisements

TREATMENT DATA INDICATORS IN THE UNODC DATA COLLECTION SYSTEM.
1 TDI &Prevalence First results of pilotproject A.W.Ouwehand W.Kuijpers Lisbon: TDI meeting september 2006.
2005 Annual report on the state of the drugs problem in Europe Name, place, date and time.
Women in treatment in the Czech Republic Běla Studničková, M. D., Vladimír Polanecký, M. D. Drug Epidemiology Headquarters Hygienic Station of the Capital.
Etienne Maffli Swiss Institute for the Prevention of Alcohol and other Drug Problems Lausanne, Switzerland Characteristics of male and female outpatients.
Working Group on coverage of Treatment Demand Data Lisbon, 5 February 2007.
Treatment Demand Data: a breakdown by gender in some EU countries Linda Montanari, Colin Taylor, Lisbon, September 2004 Annual Expert Meeting on.
Status of progress of TDI indicator Notrbert Frost, Linda Montanari, EMCDDA, September 2004 Annual Expert Meeting on Treatment Demand Indicator.
REPORT Full report Executive summary Methodology STATISTICAL ANNEX Seizures Drug use Prices Illicit laboratories.
Overview of the 2011 Work Programme Paul Griffiths Scientific committee meeting, Lisbon, November 2010.
Healthy life expectancy in the EU 15 Carol Jagger EHEMU team Europe Blanche XXVI Living Longer but Healthier lives Budapest November 2005.
2 emcdda.europa.eu European drug report package A comprehensive analysis on the drugs problem in Europe.
Problem drug use, HIV and injecting: an overview of the European experience Paul Griffiths, EMCDDA Drug Control in the Baltic Region, Vilnius, 27 September.
Bill Edgar (Dundee University) Matt Harrison (RIS) Volker Busch-Geertsema (GISS) European Commission MPHASIS Mutual Progress on Homelessness through Advancing.
Overview of the 2010 work programme Paul Griffiths, Roland Simon, Rosemary de Sousa Scientific Committee meeting, Lisbon, November 2009.
Strenghtening collaboration with Serbia - IPA4 Project expected outcomes Frédéric Denecker, Programme Management Officer Reitox and International Cooperation.
ARQ part II data management Training pack 1: Content and conceptual issues.
Disability free Life Expectancy Carol Jagger University of Leicester EHEMU Team European Population Day: Ageing IUSSP Tours 2005.
Indicators of health and disease frequency measures
Drug use, related problems and interventions targeting drug users in prison in the European countries: main issues and challenges for the future Linda.
ISARE : Health indicators in the regions of Europe André Ochoa for Isare team ISARE : Health indicators in the regions of Europe André Ochoa for Isare.
European Monitoring Centre for Drugs and Drug Addiction Margareta Nilson ISAJE, Helsinki, 1 September 2006.
Nathalie Moreau Anne Hublet Alcohol use in year olds in Belgium. Results from the Health Behaviour in School-aged Children.
The UK Drugs Situation: Data, information and uses Charlotte Davies, UK Focal Point Project Manager 1.
Estimation of the Prevalence of Problem Drug Use in Lithuania Dr Gordon Hay Centre for Drug Misuse Research University of Glasgow, United Kingdom.
An EMCDDA view on recovery Roland Simon Head of Unit Intervention, Best Practice, and Scientific Partners.
Quality Assurance at the European Monitoring Centre for Drugs and Drug Addiction Sandrine Sleiman European Conference on Quality in Official Statistics,
National Research and Development Centre for Welfare and Health Knowledge for welfare and health1 Finnish Drug Treatment Information System Kristiina Kuussaari,
Jennifer Hillebrand, „Rehabilitation of Drug Addicted Persons: Experience of Lithuania and European Countries”, 18 October 2007 Improving drug treatment.
Treatment system-based data collection: an integrated approach to monitoring Expert meeting: Implementation of the treatment strategy EMCDDA Lisbon,
Polydrug use challenges – European experience International Conference: New trends in drug use: facts and solutions, Parliament of the Republic of Vilnius.
HARM REDUCTION RESPONSES TO DRUGS IN THE EUROPEAN UNION – FROM MARGIN TO MAINSTREAM 8 th Annual Meeting of the European Red Cross / Red Crescent Network.
Annual report 2010: the state of the drugs problem in Europe.
Annual report 2009: the state of the drugs problem in Europe International Conference: New trends in drug use: facts and solutions, Parliament of the Republic.
An overview of European trends and developments Roland Simon ECAD Meeting 2011, Varna.
Statistics about unknown primary tumors Riccardo Capocaccia National Centre for Epidemiology, Surveillance and Health Promotion Istituto Superiore di Sanità,
GENDER MATTERS IN TREATMENT DEMAND Isidore S. Obot, Ph.D., M.P.H. Department of Mental Health and Substance Abuse World Health organization Geneva, Switzerland.
Erik Iversen, Norway Workshop at the annual TDI expert meeting EMCDDA, Lisbon 25 September 2006 Data Coverage Assessment The Bergen Clinics Foundation,
Revision of Problem Drug Use indicator Danica Klempová and Julián Vicente 42nd Reitox HFP meeting, 27 May 2010.
Overview of EMCDDA’s Scientific Work Paul Griffiths, Roland Simon – Scientific committee Meeting, February 2008.
HCV in injecting drug users: developing indicators of prevalence and responses VHPB WHO Consultation Meeting Geneva, 13 May 2002 Lucas Wiessing European.
Global Toolkit on Treatment Demand Data State of Progress Michael Donmall (Co-ordinator Joint Project) N ational D rug E vidence C entre.
EMCDDA Work Programme Key Issue 1: Key Indicators 30th Meeting of Scientific Committee J Vicente (together with D Olszewski, D Klempova, L Montanari,
Module 1 General introduction to substitution treatment.
Mats Wallin Swedish Univ. of Agricultural Sciences Dept. of Environmental Assessment Catarina Johansson Swedish Environmental Protection Agency Development.
XXI Congresso Nazionale SICOB - Cagliari Aprile 2013 ANALISI FATTORIALE DELL’OBESITÀ NELLA U.E.: SESSO, ETÀ, EDUCAZIONE Dott. Vincenzo Borrelli.
Health care trajectories and medication consumption of substance users in treatment : linking TDI and IMA databases (Belgium) De Ridder Karin, Antoine.
Overview of EMCDDA’s 2009 Scientific Work Programme Paul Griffiths, Roland Simon - REITOX Meeting, Lisbon, November 2007.
2010 HIV/AIDS surveillance in Europe European Centre for Disease Prevention and Control, Stockholm WHO Regional Office for Europe, Copenhagen.
Regular and intensive use of cannabis and related problems: Some results from literature and from the 2002 REITOX reports (CT P1) Roland Simon.
WOMEN PROFILE AND GENDER ANALYSIS IN TREATMENT DATA UNODC DATA.
Monitoring and reporting on the drug phenomenon in Europe EMCDDA mandate and activities Wolfgang Götz, Scientific Committee, Palmela, 14 February 2008.
USAGE OF DRUGS IN EUROPE LSD CANNABIS. ALL ADULTS (15-64) USAGE OF LSD IN EUROPE All adults (15-64) Usage of LSD in Europe datesample sizemalefemaletotal.
Data quality and feedback from the assessment on 2000 and 2001 TDI data 1 EMCDDA, TDI meeting, 23/24 June 2003 Luis Royuela.
PREVENTION OF DRUG ABUSE AMONG VULNERABLE GROUPS Dr Marcus Roberts Director of Policy and Membership DRUGSCOPE.
Collaboration between the national EWS and treatment service providers in Hungary Anna Péterfi Hungarian National Focal Point TAIEX seminar Zagreb,
Overview of the cannabis use in Europe Paul Griffiths, Reitox academy, Berlin, 29th March 2007.
Alcohol and Drug Problem in Poland. Implications for policy Janusz Sierosławski Institute of Psychiatry i Neurology 3rd Meeting of the Expert Group on.
Dagmar Hedrich, Linda Montanari, Alessandra Bo, Bruno Guarita, Chloé Carpentier, Isabelle Giraudon, Luis Royuela, Lucas Wiessing « Good prison health –
European Questionnaire on Drug Use among Prisoners - EQDP
Cannabis epidemic or return of opoid problems or decrease of high risk drug use among young adults in Austria Addictions Lisbon 2017, Paper Session 2 –
Freya Vander Laenen STRUCTURED SESSION Costs of drug treatment
Monitoring drug-related crime in Europe: state of play
Isabelle Giraudon Lisbon, 25 October 2017
Take-home naloxone as integral part of toolkits for public health providers: priorities across settings Dagmar Hedrich, EMCDDA Lisbon, 25 October 2017.
Linda Montanari Programme P1: Monitoring the Situation
“Mobility into and out of poverty in 14 European countries”
Cost of Mobile Communications Study
Skopje, 21 November 2017, General Population Survey results– launch
Presentation transcript:

Linda Montanari, Buenos Aires, October 2003 CICAD/OAS, Demand Reduction Experts Group Meeting The Information System on Treatment Demand in EU EMCDDA

To provide the Community and the EU Member States with objective, reliable and comparable information concerning drugs and drug addiction and their consequences Further information: Mission of the EMCDDA

Collecting and analysing existing data Improving data- comparison methods Disseminating data and information Tasks SituationResponsesImpact Areas

Map of EU Member States, Norway, acceding and candidate countries

Situation analysis: Working methods Key indicators Core data and developing areas Expert groups Reporting guidelines Analytical project groups

Extent and patterns of drug use in the general population Prevalence of problem drug use Drug-related deaths and mortality among drug users Treatment demand Drug-related infectious diseases Key indicators A common language for describing the drug situation

Crime Arrest Data Drug Related Crime Drug Markets & Availability Perceived availability Seizures Price & Purity Social Exclusion Youth and vulnerability New Trends Core data and developing areas

Treatment Demand Indicator TDI One of the 5 key Indicators at the EMCDDA Provide information on the people demanding treatment in the specialised drug services in Europe Further information:

What is the objective? To provide comparable, reliable and anonymous information on: Number of people treated for their drug use Characteristics and Profile of clients Patterns of use Trends over time

What is the purpose? Indirect indicator of trends in problem drug use Identification of patterns of drug use Basis for other methodologies on problem drug use prevalence estimation Identify patterns of use of services and plan and evaluation of services

Which questions the TDI answer to? Treatment contact details centre type, time of treatment, source of referral Socio-demographic information gender, age, living and labour status, education, nationality Drug related information primary and secondary drug, substitution treatment, route of administration, frequency of use, age at first use Information in TDI: 20 items What drug treatment? Which substances / Patterns of use? What characteristics of clients?

Guidelines A joint EMCDDA/Pompidou Group protocol (TDI protocol), with definitions and guidelines for data collection TDI Protocol /situation/treatment_indicator_report.pdf

How data are collected? 23 excel sheets (cross tabulations) inserted in a central EMCDDA database (EISDD) By centre type: outpatient, inpatient, low threshold, GPs, prison, others By each country (29): 15 Member States + Norway + 10 acceding countries + 3 candidate countries

What are the main resources? Network: one expert identified in each country by the NFP Working group in most of the countries involving professionals from the treatment centres at national level European annual expert meeting: the state of progress and future perspectives Small thematic working group (e.g. data coverage and cannabis data in 2003)

Some Results Clients admitted to drug treatment in 2001: trends and patterns of use

Percent of new clients admitted to treatment by main drug in 2001 Source: 2002 Reitox National Reports; Standard Table 3; 2001 data All Centre Types; N.cases: (new clients) Countries included: Dk, Ge, Gr, Sp, IR (2000 data), Nl, FI, Sw Weighted average on the total numbers of new clients by country

Percent of new clients by main drug Source: REITOX National Reports - Standard Table 3 –2001 data (*) 2000 data – All centre types

% of new clients admitted to treatment for opiates, cocaine, cannnabis in some EU countries to Source: Reitox National Reports; Standard Table 4; All Centre Types Countries included: Dk, Ge, Gr, Sp, Nl, Sw Average weighted on the number of clients by country

Percent of new outpatient clients in some country by source of referral Source: Reitox National Reports 2002 – TDI data -Outpatient Treatment Centres – Valid per cent, n = cases, new clients - * Ireland: 2000 data (n. 689) (n. 488) (n. 4700) (n. 1258) (n. 831) (n. 5970) *

Mean age of clients in treatment in 2001 New clients All clients (n = 83571)(n ) Denmark Germany Greece Spain Italy Luxembourg The Netherlands Finland Sweden United Kingdomn.a.28.3 Source: REITOX National Reports - Standard Table 3 – 2001 data All centre types Opiates and Cocaine between and Stimulants and cannabis between and 20-29

Gender distribution among new clients in 2001 Source: Reitox National Reports - Outpatient Treatment Centres N. Cases: n Countries: Dk, Ge, Gr, Sp, Nl, Fi, Sw Mainly males: 79.2 males / 20.8 females Differences between drugs: Opiates:81.2 males / 18.8 females Cocaine:85.0 males / 15.0 females Stimulants:67.5 males / 32.5 females Cannabis: 85.8 males / 14.2 females Highest proportion of males in Spain (84.9), lowest in Sweden (69.1)

Percent of new outpatient clients by level of education in 2001 Source: Reitox National Reports 2002 – TDI data -Outpatient Treatment Centres Valid per cent, n = cases, new clients Countries: Dk, Ge, Gr, Nl, Sp, Fin, Sw

Percent of new outpatient clients by labour status among in 2001 Source: Reitox National Reports 2002 – TDI data -Outpatient Treatment Centres Valid per cent, n = cases, new clients Countries: Dk, Ge, Gr, Nl, Sp, Fin, Sw 8.2% in general population

Age at first use of main drug among new clients in some countries Source: 2002 Reitox National Reports – Outpatient Treatment Centres Year covered: 2001 Countries covered: Dk, Ge, Gr, Sp, Fin, Sw

Frequency of use of main drug: % new clients in 2001 (last 30 days before starting treatment) Source: 2002 Reitox National Reports – TDI data – Outpatient Treatment Centres Year covered: 2001 Countries covered: 2001: Dk, Ge, Gr, Nl, Fin, Sw %

Route of administration among all and new clients in some country in 2001 Source: Reitox National Reports 2002 – TDI data -Outpatient Treatment Centres Countries: Dk, Ge, Gr, Ir (2000 data), Nl, Sp, Fin, Sw, Uk (all clients)

Most used secondary drugs among new clients in 2001 in some countries Source: Reitox National Reports 2002 – TDI data -Outpatient Treatment Centres Valid per cent, n using a secondar drug (n = total new clients) Countries: Dk, Ge, Gr, Nl, Sp, Fin, Sw % 85.1% use more than one drug

Opiates main substance, followed by cannabis and cocaine Decrease of opiates users, increase cannabis and cocaine Clients are males in their 20s or 30s Clients demand treatment spontaneously or through family Social conditions are worsening than general population Clients start to use in the adolescence: earlier for cannabis Conclusions (1)

Polarization of frequency of use for opiates and cocaine graduation for stimulants and especially cannabis Clients tend to inject opiates, sniff cocaine, eat stimulants: less injection among new clients Polydrug use is apparent, with cannabis as main secondary drug, followed by cocaine Relevant differences between countries Conclusions (2)

Further information on the 2003 EU drug situation: